Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in ER-positive, HER2-positive Breast Cancer (neoPEHP): an Exploratory, Open-label, Multi-center Phase 2 Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04858516

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:38:12.487981+00:00

Published At

2021-04-26T00:00:00+00:00

Record Updated At

2021-04-26

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2021-04-26"

protocolSection.identificationModule.nctId

"NCT04858516"

protocolSection.identificationModule.officialTitle

"Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in ER-positive, HER2-positive Breast Cancer (neoPEHP): an Exploratory, Open-label, Multi-center Phase 2 Study"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.